A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

NCT04702880 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive-stage Small Cell Lung Cancer

Interventions

BIOLOGICAL: BMS-986012
DRUG: Carboplatin
DRUG: Etoposide
BIOLOGICAL: Nivolumab

Sponsor

Bristol-Myers Squibb